Skip to main content

Table 1 Data analysis of included studies

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Study

N

Male

Female

Age (average)

Resource of tumor

Volume of MPE(N)

Quality of Life (KPS)

End point

NSCLC

SCLC

Gastrointestinal tumor

Breast cancer

Lymphoma

Others

Changjie H 2001 [15]

60

44

16

30ā€“76

27

4

11

10

8

Moderate-large

>ā€‰60

ORR, DCR, AEs

Xiuzhi Y 2001 [16]

60

24

36

40ā€“75

56

0

0

0

4

ā€“

ā€“

ORR, DCR, AEs

Zhuo S 2004 [17]

62

ā€“

ā€“

ā€“

55

0

0

0

7

ā€“

>ā€‰50

ORR, DCR, QOL, AEs

Junyan W 2005 [18]

82

57

25

33ā€“78

68

0

10

0

4

ā€“

>ā€‰50

ORR, DCR, AEs

Haiying X 2009 [19]

63

35

28

35ā€“71

63

0

0

0

0

ā€“

>ā€‰60

ORR, DCR, AEs

Xiaoxia H 2009 [20]

72

ā€“

ā€“

ā€“

65

0

0

0

7

Small (8)

Moderate (39)

Large (25)

>ā€‰60

ORR, DCR, QOL, AEs

Lizheng C 2009 [21]

86

62

24

25ā€“75

23

0

27

17

8

11

Large(29)

Moderate(57)

>ā€‰60

ORR, DCR, AEs

Jinguang C 2009 [22]

62

28

34

41ā€“77

52

10

0

0

0

0

ā€“

>ā€‰60

ORR, DCR, AEs

Junfeng W 2010 [23]

82

48

34

30ā€“80

54

0

15

0

13

Large(56)

Moderate(26)

>ā€‰60

ORR, DCR, AEs

Jingping Z 2010 [24]

124

80

44

47ā€“73

124

0

0

0

0

Large(84)

Moderate(40)

>ā€‰60

ORR, DCR, AEs

Cheng X 2010 [25]

62

28

34

19ā€“81

40

0

9

13

Ā 

ā€“

>ā€‰70

ORR, DCR, AEs

Fang S 2011 [26]

60

31

29

38ā€“76

41

8

2

7

2

0

Large(34)

Moderate(17)

>ā€‰40

ORR, DCR, QOL, AEs

Xueling L 2011 [27]

68

40

28

30ā€“75

40

10

8

0

10

ā€“

>ā€‰60

ORR, DCR, AEs

Yan Q 2011 [28]

76

45

31

46ā€“77

76

0

0

0

0

ā€“

>ā€‰60

ORR, DCR, AEs

Li J 2013 [29]

73

40

33

35ā€“74

31

16

26

0

0

Large(41)

Moderate(32)

>ā€‰60

ORR, DCR, QOL, AEs

Lijie H 2014 [30]

60

38

22

39ā€“78

60

0

0

0

0

Large

>ā€‰50

ORR, DCR, QOL, AEs

Miao H 2016 [31]

61

40

21

38ā€“75

42

0

8

6

5

Large

>ā€‰60

ORR, DCR, AEs

Baohua Y 2017 [32]

66

35

31

42ā€“76

ā€“

ā€“

ā€“

ā€“

ā€“

ā€“

ā€“

>ā€‰60

RR, DCR

  1. N number of patients, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, MPE malignant pleural effusions, KPS karnofsky physical status score, ORR objective response rate, DCR, disease control rate, QOL quality of life, AEs adverse effects